← Leaderboards
Reeder McNeil Robinson
Leukogene Therapeutics, Inc.
$2,940,211
Attributed
$2,940,211
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $782.7K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,940,211 · 2
By mechanism
R44$2,268,465 · 1
R42$671,746 · 1
Top collaborators
No co-investigators on record.
Most similar at Leukogene Therapeutics, Inc.
Same institution · by research overlap
- Frank W. Marcoux$2,447,659
Others in their field
Other Rising Stars on “Checkpoint Inhibition”
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- Xu Chen · University Of California, San Francisco$3,581,285
- Yuwen Zhu · University Of Colorado Denver$3,496,594
- Ioannis Vlachos · Beth Israel Deaconess Medical Center$3,412,120
- Mark Yarchoan · Johns Hopkins University$2,710,792
- Akash Patnaik · University Of Chicago$2,630,502
Research focus
Checkpoint InhibitionCell LineAffinityCellsAdenocarcinomaAnimalsAnteriorAntigen-Presenting CellsAntigensAntibody Titer MeasurementAnti-CancerBindingBiochemistryBiological MarkersBioluminescence ImagingBloodB-LymphocytesBody SystemC57bl/6 MouseCancer ModelCancer TherapyCancer VaccinesCarrier ProteinsChemotherapy
Grant awards (4)
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma$742,887
R44 · FY2025 · CA · contact PI
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma$742,887
R44 · FY2024 · CA · contact PI
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma$782,691
R44 · FY2023 · CA · contact PI
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma$671,746
R42 · FY2022 · CA · contact PI